|Mr. J. Scott Wolchko||Founder, CEO, Pres & Director||976k||25.12M||1970|
|Mr. Edward J. Dulac III||Chief Financial Officer||588k||821.37k||1976|
|Dr. Mark Plavsic D.V.M., Ph.D.||Chief Technical Officer||634.51k||N/A||1961|
|Ms. Cindy R. Tahl||Gen. Counsel & Corp. Sec.||602k||13.37M||1973|
|Dr. Bahram Valamehr Ph.D.||Chief R&D Officer||602k||7.11M||1977|
|Dr. Yu-Waye Chu M.D.||Chief Medical Officer||602k||263.51k||N/A|
|Mr. Jim Beitel M.B.A.||Sr. VP of Corp. Devel.||N/A||N/A||N/A|
|Dr. Sarah Cooley||Sr. VP of Clinical Translation||N/A||N/A||N/A|
|Dr. Jerome Bressi Ph.D.||Sr. VP of Regulatory Affairs & Quality Assurance||N/A||N/A||N/A|
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Fate Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 8; Compensation: 9.